Vagulienė N. THE PEMBREIZH MULTICENTER REAL-LIFE COHORT STUDY: FIRST LINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥50%. PIA [Internet]. 2020Sep.17 [cited 2026Nov.12];4(2):164-7. Available from: https://ejournals.vitaelitera.lt/index.php/PIA/article/view/119